信达生物(01801)启动玛仕度肽VS司美格鲁肽治疗代谢相关脂肪性肝病III期临床

智通财经网
17 Mar

智通财经APP获悉,3月14日,药物临床试验登记与信息公示平台显示,信达(01801)启动了一项在中国超重或肥胖合并代谢相关脂肪性肝病(MAFLD)受试者中比较玛仕度肽与司美格鲁肽有效性和安全性的多中心、随机、开放标签的III期临床研究(GLORY-3)。

玛仕度肽(IBI362)是信达生物礼来制药共同推进的一款胰高血糖素样肽-1受体(GLP-1R)/胰高血糖素受体(GCGR)双重激动剂。作为一种人体内天然存在的胃泌酸调节素(OXM)类似物,玛仕度肽除了通过激动GLP-1R促进胰岛素分泌、降低血糖和减轻体重外,还可通过激动GCGR增加能量消耗增强减重疗效,同时改善肝脏脂肪代谢。

玛仕度肽已在多项临床研究中展现出优秀的减重和降糖疗效,以及降低腰围、血脂、血压、血尿酸、肝酶及肝脏脂肪含量,以及改善胰岛素敏感性,带来多重代谢获益。目前,玛仕度肽在中国超重或肥胖(GLORY-1和GLORY-2)受试者和2型糖尿病(DREAMS-1,DREAMS-2和DREAMS-3)受试者中的多项III期临床研究正在进行中。其中, GLORY-1和DREAMS-2研究已经达成主要终点。

更多港股重磅资讯,下载智通财经app

更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10